Fly News Breaks for September 18, 2017
NBRV
Sep 18, 2017 | 12:32 EDT
Wedbush analyst Robert Driscoll raised his price target for Nabriva Therapeutics to $21 from $13 after the company's Phase 3 study for lefamulin against pneumonia met the primary endpoint. The analyst calls the data a "giant leap" for lefamulin. He has an Outperform rating on Nabriva. The shares in midday trading are up 37% to $9.43.
News For NBRV From the Last 2 Days
There are no results for your query NBRV